Cited by 111TGF-β signaling in diseasesLiver physiology and pathologyT-cell and B-cell Immunology

TGF-β3 and cancer: A review

Open access
Laverty, H.G., Wakefield, L.M., Occleston, N.L., O’Kane, S., Ferguson, M.W.J.·2009·Cytokine & Growth Factor Reviews

Abstract

With the development of growth factors and growth factor modulators as therapeutics for a range of disorders, it is prudent to consider whether modulating the growth factor profile in a tissue can influence tumour initiation or progression. As recombinant human TGF-beta3 (avotermin) is being developed for the improvement of scarring in the skin it is important to understand the role, if any, of this cytokine in tumour progression. Elevated levels of TGF-beta3 expression detected in late-stage tumours have linked this cytokine with tumourigenesis, although functional data to support a causative role are lacking. While it has proved tempting for researchers to interpret a 'correlation' as a 'cause' of disease, what has often been overlooked is the normal biological role of TGF-beta3 in processes that are often subverted in tumourigenesis. Clarifying the role of this cytokine is complicated by inappropriate extrapolation of the data relating to TGF-beta1 in tumourigenesis, despite marked differences in biology between the TGF-beta isoforms. Indeed, published studies have indicated that TGF-beta3 may actually play a protective role against tumourigenesis in a range of tissues including the skin, breast, oral and gastric mucosa. Based on currently available data it is reasonable to hypothesize that administration of acute low doses of exogenous TGF-beta3 is unlikely to influence tumour initiation or progression.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cytogfr.2009.07.002

Cites

164 of 164 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A TβRII receptor antibody (IMC-TRI, LY3022859) under development by Eli Lilly showed efficacy in preclinical evaluation against mammary cancer.

    “Finally, a TβRII receptor antibody (IMC-TRI, LY3022859) under development by Eli Lilly showed efficacy in preclinical evaluation against mammary cancer304”

    From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [304]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

12 of the 176 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. [64]MacDougall JR, Kobayashi H, Kerbel RS. Responsiveness of normal dysplastic melanocytes and melanoma cells from different lesional stages of disease progression to the growth inhibitory effects of TGF-β. Mol Cell Different 1993; 1: 21– 40.

Cited by

Sorted by citations

Authors
Laverty, H. G., Wakefield, L. M., Occleston, N. L., O’Kane, S., & Ferguson, M. W. J.
Affiliations
  • Renovo (United Kingdom) (GB)
  • National Institutes of Health (US)
Corresponding author
Ferguson, M.W.J.
Venue
Cytokine & Growth Factor Reviews
Publisher
Elsevier BV
Published
2009-08
Volume
20
Issue
4
Pages
305-317
ISSN
1359-6101 (ISSN-L)
OpenAlex
W2025475845
Cited by
110
References
176
Citations by year
2026: 7 · 2025: 8 · 2024: 12 · 2023: 8 · 2022: 3 · 2021: 4 · 2020: 7 · 2019: 2 · 2018: 9 · 2017: 9 · 2016: 8 · 2015: 8 · 2014: 3 · 2013: 6 · 2012: 9
FWCI
0.41
Type
journal article
Language
en
Open access
Locations
  • Cytokine & Growth Factor Reviews (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health
  • National Cancer Institute (Z01BC010881)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
TGF-beta3, tumourigenesis, tumor progression, TGF-beta isoforms, TGF-β1, growth factor therapy, tumor suppression, scar tissue, breast cancer, oral mucosa, gastric mucosa
MeSH terms
Amino Acid Sequence, Animals, Humans, Models, Molecular, Molecular Conformation, Molecular Sequence Data, Neoplasms, Sequence Homology, Amino Acid, Protein Isoforms, Transforming Growth Factor beta3

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review